Related Experiment Video
Updated: Jan 24, 2026
Study of the DNA Damage Checkpoint using Xenopus Egg Extracts
Published on: November 5, 2012
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All
Charlene M Fares1, Eliezer M Van Allen2, Charles G Drake3
11 Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA.
Abstract:
The emergence of immune checkpoint blockade therapies over the last decade has transformed cancer treatment in a wide range of tumor types. Unprecedented and durable clinical responses in difficult-to-treat cancer histologies have been observed. However, despite these promising long-term responses, the majority of patients fail to respond to immune checkpoint blockade, demonstrating primary resistance. Additionally, many of those who initially respond to treatment eventually experience relapse secondary to acquired resistance. Both primary and acquired resistance are a result of complex and constantly evolving interactions between cancer cells and the immune system. Many mechanisms of resistance have been characterized to date, and more continue to be uncovered. By elucidating and targeting mechanisms of resistance, treatments can be tailored to improve clinical outcomes. This review will discuss the landscape of immune checkpoint blockade response data, different resistance mechanisms, and potential therapeutic strategies to overcome resistance.
Insights
Immune checkpoint blockade offers durable cancer responses but faces primary and acquired resistance. Understanding and targeting resistance mechanisms is key to improving patient outcomes.
Area of Science:
- Immunology
- Oncology
- Cancer Therapy
Background:
- Immune checkpoint blockade (ICB) therapies have revolutionized cancer treatment, yielding durable responses in various tumor types.
- Despite successes, a significant proportion of patients exhibit primary resistance, and others develop acquired resistance after initial response.
- Resistance to ICB is driven by complex, dynamic interactions between cancer cells and the immune system.
Purpose of the Study:
- To review the current landscape of ICB response data.
- To elucidate diverse mechanisms underlying primary and acquired resistance to ICB.
- To discuss emerging therapeutic strategies aimed at overcoming ICB resistance.
Main Methods:
- Comprehensive literature review of studies on ICB response and resistance.
- Analysis of characterized mechanisms of primary and acquired resistance.
- Synthesis of data on novel therapeutic approaches targeting resistance pathways.
Main Results:
- ICB has transformed treatment for many cancers, but resistance remains a major clinical challenge.
- Multiple resistance mechanisms, involving tumor-intrinsic and extrinsic factors, have been identified.
- Ongoing research continues to uncover novel pathways contributing to ICB resistance.
Conclusions:
- Understanding the multifaceted mechanisms of ICB resistance is crucial for clinical success.
- Targeting specific resistance pathways holds promise for improving patient responses and overcoming treatment failure.
- Personalized therapeutic strategies tailored to individual resistance profiles are essential for maximizing the efficacy of ICB.
Related Concept Videos
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
01:29Neuromuscular Junction And Blockade
01:38What is the Immune System?
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:27Tumor Immunotherapy
01:36Humoral Immune Responses